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Diagnosis and management of combined post- and precapillary 
pulmonary hypertension in a patient with multiple comorbidities
Abstract
Diagnosis of pulmonary hypertension requires a laborious investigation that must be performed in accordance with international 
guidelines. Right-heart catheterization is the gold standard examination to assess the degree of hemodynamic impairment of 
post- or precapillary origin, guiding management. The presence of comorbidities is becoming rather frequent in real-life pulmonary 
hypertension cases, thus creating diagnostic and therapeutic complexity. We present a case of combined post- and precapillary 
pulmonary hypertension in a patient with ischemic heart disease and combined pulmonary fibrosis and emphysema, in order to 
describe the diagnostic algorithm for pulmonary hypertension and elucidate the problematic aspects of managing this debilitating 
disease in a patient with several comorbidities. Current guidelines do not support the use of specific vasodilator treatment in group 
II -due to heart disease and group III-due to lung disease pulmonary hypertension, unless the patient presents with severe pulmo-
nary hypertension (mean pulmonary artery pressure>35 mm Hg or cardiac index < 2.0 L/min) with right ventricular dysfunction 
and is treated in an expert center and preferably in the context of a randomized control trial. In the case presented, therapeutic 
management focused, firstly, on treatment of the underlying heart and lung disease and, subsequently, on specific vasoactive 
therapy, due to severe hemodynamic deterioration.
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Introduction
Pulmonary hypertension (PH) arises as a com-
plication of chronic lung or heart disease, in-
creasing morbidity and mortality of the primary 
disease. Diagnosis requires early clinical suspi-
cion and a laborious investigation. Currently, 
there is no approved treatment for PH associated 
with chronic lung disease and heart failure. The 
objective of this presentation is to describe the 
diagnostic algorithm for pulmonary hypertension 
and elucidate the problematic aspects of man-
aging this debilitating disease in a patient with 
several comorbidities.
Material and methods
A 70-year-old white male (BMI 30.6 kg/m2) 
presented with worsening dyspnea and fatigue 
during the last 6 months. He also reported ret-
rosternal chest pain during activity lasting less 
than 10 minutes. He suffered from emphysema and 
bronchiectasis and had a history of pneumothorax 
that was surgically managed by lung decortication 
15 years ago. He was a former smoker with a smok-
ing history of 45 pack/years. His medical history 
also included atrial fibrillation, coronary artery 
disease that led to coronary artery bypass grafting 
10 years ago, goitre and gastroesophageal reflux.
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On clinical examination, he presented nor-
mal blood pressure (125/72 mm Hg), tachycar-
dia (95 beats/min), elevated respiratory rate 
(19 breaths/min) and low oxygen saturation 
(SaO2% 88%) on room air. On chest ausculta-
tion, lung sounds were diminished uniformly, 
and bibasilar crackles were found. He present-
ed jugular venous enlargement and mild leg 
edemas. Cardiac pulse was irregular and loud 
P2 sound was present. Examination of the ab-
domen was normal.
Blood cell count and the basic biochemical 
panel were normal, along with thyroid function. 
The BNP value was 307 ng/L. Blood gas analysis 
revealed mild hypercapnia and hypoxemia on 
room air. Diffusion capacity (DLCO: 25%) was se-
verely diminished, and lung volumes were mildly 
abnormal (FEV1: 80%, FVC: 84%, FEV1%: 72, TLC: 
62%, RV: 38%), implying coexistence of restrictive 
and vascular pathophysiology. 6-minute walking 
test (6MWT) was 328 m with desaturation from 
92% to 84% while receiving oxygen at a flow of 
4 lt/min.
Chest X-ray revealed a reticular pattern in the 
lower lung area bilaterally, and high-resolution 
computed tomography (HRCT) confirmed new 
moderate fibrosis of usual interstitial pneumonia 
(UIP) pattern in the lower lobes (Figure 1). The 
upper lobes presented emphysema, comprising 
the diagnosis of combined pulmonary fibrosis 
and emphysema (CPFE).
Heart ultrasonography revealed an ejection 
fraction of 50% and diastolic dysfunction of 
the left ventricle, severe dilatation of the right 
ventricle with impaired systolic function, mod-
erate insufficiency of the tricuspid valve and an 
estimated systolic pressure of the right ventricle 
of 70 mm Hg. Ventilation-perfusion scintigraphy 
was negative for pulmonary embolism. 
Cardiopulmonary exercise testing (CPET) 
followed in order to discriminate between car-
diac and respiratory cause of dyspnea, assess 
functional capacity, the degree of desaturation 
and the need for oxygen therapy. The patient 
had reduced peak oxygen consumption (65% 
pred), decreased anaerobic threshold (54% pred), 
elevated ratio of minute ventilation to CO2 pro-
duction (46), reduced ventilatory reserve (10lt), 
and a nadir saturation of 82%. These values were 
compatible with lowered functional capacity due 
to respiratory limitation and increased pulmonary 
vascular resistance. 
The patient underwent right-heart cathe-
terization (RHC) revealing combined pre-and 
post-capillary PH (CpcPH). He had a mean pul-
monary pressure (mPAP) of 32 mm Hg, pulmonary 
wedge pressure (PAWP) of 16 mm Hg, pulmonary 
vascular resistance (PVR) of 3.2 WI, cardiac index 
(CI) of 3.5 L/min/m2 and a diastolic pulmonary 
gradient (DPG) of 9 mmHg. According to hemo-
dynamic values, the man was classified as group 
II-due to heart disease and group III-due to lung 
disease PH. Current guidelines do not support 
the use of the approved therapies for pulmonary 
arterial hypertension (PAH) in these two groups, 
unless the patient presents with severe pulmo-
nary hypertension (mPAP > 35 mm Hg or CI 
< 2.0 L/min) with right ventricular dysfunction 
and is treated in an expert center and preferably 
in the context of a randomized control trial. Fu-
rosemide and continuous oxygen therapy were 
initiated. The patient was already receiving per-
indopril, bisoprolol, rivaroxaban, simvastatin, 
and omeprazole. Low-salt and low-fat intake and 
mild exercise, as tolerated, were recommended. 
Moreover, the man received nintedanib, an an-
ti-fibrotic agent as treatment for his lung disease. 
However, he presented severe gastroesophageal 
reflux disease that led to immediate discontin-
uation of treatment. Pirfenidone could not be 
prescribed as alternative anti-fibrotic treatment 
due to insurance coverage reasons.
Figure 1. Chest computed tomography
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The patient did not present for follow-up and 
returned deteriorated one year after. His dyspnea 
occurred in simple tasks, with immediate severe 
desaturation. We repeated a CT angiography 
that was negative for pulmonary embolism. 
Heart ultrasonography presented deterioration 
with severe enlargement of the right ventricle 
with flattening of intraventricular septum and 
a D-shaped left ventricle. The BNP value in-
creased to 897 ng/L. A second RHC revealed an 
elevated mPAP of 49 mm Hg, PVR of 4.3 WI and 
normal wedge pressure under diuretic treatment. 
We decided to initiate sildenafil, a PDE-5 inhibi-
tor, in combination with inhaled iloprost, a pros-
tanoid analogue, due to the severe impairment of 
hemodynamics. The patient improved transiently 
but disease progression led to the unfortunate 
event of death four months later.
Discussion
The case presented is characterized by chal-
lenging complexity. The first RHC revealed CpcPH, 
as PAWP was > 15 mm Hg and PVR was > 3 WI 
[1]. Ischemic heart disease explained the post-cap-
illary element of the hemodynamic derangement. 
The precapillary element was attributed to chronic 
lung disease, based on the extensive findings on 
HRCT. The discrimination between group 1 and 
3 PH often requires a comprehensive investigation 
of several criteria, including spirometry, CPET, 
hemodynamic profile, radiologic findings and PAH 
risk factors [2]. In our case, the spirometry was 
not representative of the extent of lung disease 
and could mistakenly favor the diagnosis of group 
1 PAH, as in CPFE, lung volumes appear normal 
or mildly abnormal due to the opposite effects of 
expiratory flow and lung volumes [3].
Moreover, at the time of the first RHC, PH 
was classified as non-severe, and treatment was 
focused on the underlying lung and heart disease 
[4]. Currently, the well-established PAH therapies 
are not approved in groups 2 and 3 PH, as the 
results from existing studies have been unfavor-
able [4–7].
Specifically, no multicenter trial exists to 
support a benefit of vasoactive drugs in group 
2 PH [1, 4]. On the contrary, disappointing re-
sults from trials testing the efficacy of sildenafil, 
macitentan, riociguat, epoprostenol and others 
have accumulated [1]. However, several trials 
are ongoing to examine the use of these drugs in 
patients with heart failure with preserved ejection 
fraction (HFpEF) and CpcPH [1, 8]. A promising 
signal for this selected subgroup of patients arise 
from a few studies on sildenafil and riociguat, 
encouraging further research [9, 10].
Similarly, the use of vasodilator agents in 
group 3 PH is generally contraindicated. Endo-
thelin receptor antagonists and riociguat have 
been deemed harmful, while sildenafil has occa-
sionally been used in group 3 PH with conflicting 
results [3, 6, 7, 11]. Positive effects have also been 
reported regarding inhaled iloprost in COPD pa-
tients, inhaled and intravenous treprostinil use 
in patients with severe group 3 PH, with severe 
right ventricular dysfunction [12, 13].  
Existing literature involving the aforemen-
tioned group provides heterogenous results. Brew-
is et al reported an absence of change in 6MWT 
and FC, and an improvement of BNP levels (p = 
0.015) after specific PH therapy in 118 patients 
with severe group 3 PH [5]. Furthermore, the 
treatment effect was found dependent on lung 
disease phenotype, with CPFE presenting the 
worst outcome [5]. However, the study was lim-
ited by the absence of a control group that did 
not receive treatment [5]. 
Moreover, results from a subgroup of 151 pa-
tients of the COMPERA registry with chronic 
fibrosing interstitial pneumonias and severe PH 
indicated that PDE5-i long-term use increased 
6MWT and functional class in the short term, 
with unknown effects on survival [14].   
Another promising single arm prospective 
study included 14 patients with severe PH associ-
ated with lung disease, 6 of which were diagnosed 
with CPFE. Repeated cardiac magnetic resonance 
imaging revealed improvement of right ventricle 
dilatation and dysfunction after 3 months of treat-
ment with sildenafil, implying potential benefit 
in this group of patients [15]. 
Additional trials are currently ongoing to 
further evaluate long-term efficacy of PAH ther-
apies in severe group 3 PH [7]. Possibly, selected 
subgroups could be identified to benefit from 
these drugs, altering therapeutic strategies in 
the future [7]. To date, recent guidelines and 
recommendations underline the significance of 
referral to an expert center for the individualized 
care of a patient presenting severe hemodynamic 
derangement with coexisting lung disease [2, 4]. 
Cautious use of PH specific therapy could be con-
sidered, preferably in the context of a randomized 
control trial, with frequent follow-up assessing 
treatment effect [4, 7]. 
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